More Biotron Limited news
Biotron LimitedASX: BIT

Positive outcomes in BIT225 phase 2 clinical trial in hiv

Apr 4, 2024 at 10:58 PM EDT · Issued by Biotron Limited

Filed with ASX · Apr 4, 2024 at 10:58 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/positive-outcomes-in-bit225-phase-2-clinical-trial-in-hiv

Biotron Limited on 6ix

Earlier from Biotron

  • Response to ASX Price QueryMar 26, 2024
  • Completion of phase 2 covid clinical trialAug 16, 2023
  • Second Site Approved for Phase 2 Covid-19 TrialMay 12, 2023
  • Commencement Phase 2 Covid-19 Clinical TrialMay 3, 2023
  • Completion of Phase 2 HIV-1 Clinical TrialsMar 8, 2023

Later from Biotron

  • BIT225 Phase 2 HIV Efficacy Trial Meets Primary ObjectivesJun 19, 2024
  • BIT225-012 Phase 2 COVID-19 clinical trialSep 5, 2024
  • $1.8M R&D Rebate ReceivedOct 13, 2024
  • Agreement with C14 Consulting GroupNov 26, 2024
  • Updated Appendix 4CFeb 3, 2025
All Biotron news releases↗

Follow Biotron into a list and get an email when it puts out news.

Follow Biotron
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer